Lilly to boost diabetes sales force amid layoffs in other categories

Share this article:
Lilly Alimta patent extended to 2022
Lilly Alimta patent extended to 2022
For those looking for hints to Eli Lilly's first quarter results being posted April 26, the latest news may muddy things a bit: the company is laying off (they prefer the term "restructuring") a big chunk of its US sales force “to adapt to changing customer realities, evolutions in the health care environment and upcoming loss of exclusivity for two major products.” Those would be Cymbalta and Evista, which face generic competition in 2013 and 2014, respectively.

The changes mean the bio-medicines sales force will “move to a smaller structure that's more directly aligned with our business realities,” Lilly spokesman Scott MacGregor told MM&M. The unit includes the company's neuroscience, musculoskeletal, cardiovascular and men's health divisions.

Lilly wouldn't talk numbers, but The Wall Street Journal said the layoffs affect around 30% of the US sales force. The drug maker told MM&M that the patent fallout will be limited to the crews handling these two drugs. In a follow-up email MacGregor emphasized that the company values its reps, writing “let me be clear on one thing: we're not getting rid of our sales force.”

Contradicting the slim-down is recent news is Lilly's diabetes plans. In addition to its November announcement that  it was investing in a plant to make insulin-filled cartridges, the company announced April 2 that it was going to kick in an additional $180 million for the plants.

Sales staff are going to be part of that investment. MacGregor told MM&M the company is going to up its diabetes sales headcount for the “planned launches of two medicines in our late-stage pipeline.” Lilly and Boehringer Ingelheim submitted SGLT-2 inhibitor empagliflozin to the FDA this month.

The spokesman also noted that the job cuts won't hit the Indianapolis home base particularly hard because sales employees are spread across the country.

The company told employees about the changes Wednesday.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...